Grant of Options

RNS Number : 8578S

Hemogenyx Pharmaceuticals PLC

13 July 2020

 

13 July 2020

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Grant of Options

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the Board of Directors has agreed to grant options over a total of 6,200,626 ordinary shares of 1p each in the capital of the Company ("Share Options") to certain PDMRs and a member of the Scientific Advisory Board of the Company.

The details of the Share Options granted are set out below:

Name	Position	Number of Share Options Granted	Exercise Price (pence)	Vesting Date	Expiry Date
Peter Redmond	Non-Executive Director	2,200,000	7	Vesting in quarterly tranches over the 12 months from 13 July 2020	12 July 2025
Andrew Wright	Financial Controller (PDMR)	2,200,000	7		12 July 2025
Dr Alexander Tarakhovsky	Scientific Adviser	1,800,626	3.5	Immediate	3 October 2022

Following the grant of the Share Options, in aggregate there will be 36,753,702 ordinary shares of 1p each of the Company under option to directors, employees and members of the Scientific Advisory Board of the Company, representing 8.48% of the issued ordinary share capital of the Company.

Enquiries:

Hemogenyx Pharmaceuticals plc	www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	[e-mail]
Peter Redmond, Director
SP Angel Corporate Finance LLP	Tel: [phone]
Matthew Johnson, Vadim Alexandre, Soltan Tagiev
Peterhouse Capital Limited	Tel: [phone]
Lucy Williams, Duncan Vasey, Charles Goodfellow
US Media enquiries	Tel: [phone]
Lowell Goodman	[e-mail]

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMR") and persons closely associated with them ("PCA"):

1.	Details of PDMR/person closely associated with them
a)	Name	1.  Peter Redmond 2.  Andrew Wright
b)	Position/status	1.  Non-Executive Director 2.  Financial Controller (PDMR, non-board)
c)	Initial notification/ amendment	Initial notification
2.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument	Options over ordinary shares of 1p of Hemogenyx Pharmaceuticals plc Identification code GB00BYX3WZ24
b)	Nature of the transaction	Grant of options
c)	Price(s) and volume(s)	Price(s) Volume(s) 1.  £0.07 2.  £0.07 1.  2,200,000 2.  2,200,000
d)	Aggregated information - Aggregated volume - Price	Price(s) Volume(s) N/A - variable 4,400,000
e)	Date of the transaction	13/07/2020
f)	Place of the transaction	Outside of a trading venue

 

END

 

 

DSHMZGMNDFDGGZM